Rufinamide for the treatment of Lennox––Gastaut syndrome

Author： Besag Frank MC  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.5, 2011-04, pp. : 801-806

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK

By Benedict Ágnes  

PharmacoEconomics, Vol. 28, Iss. 3, 2010-03 ,pp. : 185-199

Adis International

Access to resources Recommend Favorite

Rufinamide: a guide to its use in Lennox-Gastaut syndrome

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 7, 2010-07 ,pp. : 6-9

Adis International

Access to resources Recommend Favorite

Rufinamide: A Pharmacoeconomic Profile of its Use as Adjunctive Therapy in Lennox-Gastaut Syndrome

By McCormack Paul L.  

PharmacoEconomics, Vol. 30, Iss. 3, 2012-03 ,pp. : 247-256

Adis International

Access to resources Recommend Favorite

Rufinamide for Pediatric Patients with Lennox-Gastaut Syndrome: A Comprehensive Overview

By >  

Pediatric Drugs, Vol. 13, Iss. 2, 2011-04 ,pp. : 97-106

Adis International

Access to resources Recommend Favorite

Treatment of Lennox-Gastaut Syndrome: Current Recommendations

By Delanty N.   French J.  

CNS Drugs, Vol. 10, Iss. 3, 1998-09 ,pp. : 181-188

Adis International

Access to resources Recommend Favorite